TY - JOUR
T1 - Drug targeting systems for inflammatory disease: one for all, all for one
AU - Crielaard, B.J.
AU - Lammers, Twan Gerardus Gertudis Maria
AU - Schiffelers, R.M.
AU - Storm, Gerrit
N1 - Special issue: Drug Delivery Research in Europe
PY - 2012
Y1 - 2012
N2 - Abstract
In various systemic disorders, structural changes in the microenvironment of diseased tissues enable both passive and active targeting of therapeutic agents to these tissues. This has led to a number of targeting approaches that enhance the accumulation of drugs in the target tissues, making drug targeting an attractive strategy for the treatment of various diseases. Remarkably, the strategic principles that form the basis of drug targeting are often employed for tumor targeting, while chronic inflammatory diseases appear to draw much less attention. To provide the reader with a general overview of the current status of drug targeting to inflammatory diseases, the passive and active targeting strategies that have been used for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS) are discussed. The last part of this review addresses the dualism of platform technology-oriented ("one for all") and disease-oriented drug targeting research ("all for one"), both of which are key elements of effective drug targeting research.
AB - Abstract
In various systemic disorders, structural changes in the microenvironment of diseased tissues enable both passive and active targeting of therapeutic agents to these tissues. This has led to a number of targeting approaches that enhance the accumulation of drugs in the target tissues, making drug targeting an attractive strategy for the treatment of various diseases. Remarkably, the strategic principles that form the basis of drug targeting are often employed for tumor targeting, while chronic inflammatory diseases appear to draw much less attention. To provide the reader with a general overview of the current status of drug targeting to inflammatory diseases, the passive and active targeting strategies that have been used for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS) are discussed. The last part of this review addresses the dualism of platform technology-oriented ("one for all") and disease-oriented drug targeting research ("all for one"), both of which are key elements of effective drug targeting research.
KW - METIS-292672
KW - IR-83081
U2 - 10.1016/j.jconrel.2011.12.014
DO - 10.1016/j.jconrel.2011.12.014
M3 - Article
VL - 161
SP - 225
EP - 234
JO - Journal of controlled release
JF - Journal of controlled release
SN - 0168-3659
IS - 2
ER -